Moonshots: Space, Longevity, and Billionaire Megaprojects

The Million Dollar Question: Jeff Bezos’s space company, Blue Origin, is 26 years old and has never turned a profit. Roughly how much of his fortune is it reported to burn through every year chasing SpaceX?
A) ~$500 million B) ~$1.2 billion C) ~$2.5 billion D) ~$4.8 billion

Read on for the answer.

A century ago, the largest American fortunes left their mark in stone: libraries, museums, concert halls, universities with a family name carved over the door. The modern version is louder and stranger. Today’s biggest fortunes fund reusable rockets, laboratories trying to reverse human aging, and bets on fusion power — projects too large, too risky, and too slow for any normal business to take on. The word everyone uses for them is “moonshot,” and it carries a built-in argument. Is this the best thing wealth can do with itself, or the most expensive way ever invented to impress people? This post is about that argument, and about how to tell, from the outside, which megaprojects are real.

What it is

A billionaire megaproject is a privately funded attempt to do something on the scale of a national program — and usually something a government either won’t do or is doing too slowly. It sits at the far end of a spectrum that runs from ordinary luxury (a yacht, a jet) through philanthropy (a hospital wing) to the moonshot: an open-ended, multibillion-dollar effort with a goal big enough that hitting it would change the world, and a real chance it never hits at all.

Four lanes cover most of them. The first is private spaceflight — SpaceX, Blue Origin, and the smaller rocket and satellite companies built to put hardware in orbit and, eventually, people on other planets. The second is radical life extension — the cluster of labs and startups trying not just to treat disease but to slow or reverse aging itself. The third is fusion and frontier energy — the decades-long quest to build a power source that runs on seawater and leaves no carbon, now funded heavily by tech fortunes. The fourth is the megaproject fringe: geoengineering experiments aimed at cooling the planet, brain-computer interfaces like Musk’s Neuralink, undersea cables, privately planned cities, and the occasional genuinely strange one-off. This lane is the hardest to assess, because it mixes serious science with publicity stunts, and the founders themselves are not always sure which they’re funding.

What unites them is ambition wildly out of proportion to any near-term return. These are not investments in the ordinary sense, even when they’re structured as companies. They are bets that a single fortune, pointed hard enough at one problem, can move it.

Who funds it

This is a $1B+ activity, full stop. The sums involved — billions a year, sustained over a decade or more — are simply out of reach below the very top of the wealth distribution. Even a $500 million net worth, enormous by any normal measure, cannot fund a rocket program; the burn rate alone would exhaust it in months. So the cast is small, and most of the names recur.

In space, the two largest efforts trace to two of the world’s richest people: Elon Musk’s SpaceX and Jeff Bezos’s Blue Origin. In longevity, the money comes from a familiar overlapping set — Bezos again (a backer of the anti-aging company Altos Labs), Google co-founder Larry Page (whose company funded the aging lab Calico), and a growing pool of sovereign money, most visibly Saudi Arabia’s Hevolution Foundation, which has signaled plans to spend on the order of $1 billion a year on healthspan research. In fusion, OpenAI’s Sam Altman is the marquee backer of Helion Energy, with Bill Gates, Peter Thiel, and others spread across rival ventures.

There is also a quieter sub-genre of personal moonshot, where the project is the funder’s own body. Bryan Johnson, who sold his payments company for a reported fortune, now spends about $2 million a year running an extreme, heavily measured anti-aging protocol on himself — a longevity megaproject with a sample size of one.

Why they fund it

“Because they can afford it” explains the budget, not the choice. People at this level could buy anything; they choose rockets and aging labs for reasons that sort into a few recognizable drives.

The first is legacy — the same impulse that built the old libraries, scaled up. A museum wing keeps a name alive for a century; a working Mars settlement or a cure for aging would keep it alive for as long as there are people. The second is status of a particular kind: not the status of owning the biggest boat, but of being seen to work on the biggest problem. In the circles these fortunes move in, funding a fusion startup signals something a private island does not. The third, and it would be cynical to dismiss it, is genuine belief — many of these founders are sincere technologists who think space settlement or defeated aging are achievable and under-resourced, and that markets and governments are failing to fund them.

A fourth motive is the problem-too-big-for-markets logic: some goals have payoffs so distant and uncertain that no investor with normal time horizons will fund them, which leaves the field to people who can afford to be patient and don’t need the return. And a fifth, specific to the longevity lane, is the most human one of all — the people funding the fight against aging are aging themselves, and unlike a museum, this is a legacy they hope to be alive to enjoy. The motives differ from the ordinary luxuries covered elsewhere on this site precisely because the goal is external: a yacht is for the owner, but a moonshot, if it works, is for everyone — which is exactly what makes it such effective status.

How it works

The funding vehicles vary, and the structure tells you a lot about how serious a given project is.

The oldest model is self-funding from share sales. For years, Bezos funded Blue Origin by selling roughly $1 billion a year of Amazon stock and pouring it in — no outside investors, no board to answer to, just one fortune underwriting one rocket company. The advantage is total control; the disadvantage is that the whole burden, and the whole risk, sits on one balance sheet.

The dominant modern model is the founder-led startup that also raises outside capital. SpaceX is the template: a real company with paying customers (satellite launches, the Starlink internet service) whose revenue helps fund the moonshot part (Starship, Mars). That mix is why SpaceX is treated as a serious business rather than a vanity project — it generated close to $16 billion in revenue in 2025, most of it from Starlink, and has been the subject of persistent reporting about a possible IPO at a valuation in the trillion-dollar range. Whether that valuation holds is exactly the kind of claim to treat with caution; what’s verifiable is that the company ships hardware and books real revenue.

A third model is the mission-driven lab or foundation, funded by a single large commitment rather than a revenue stream — Calico, Altos Labs, Hevolution. These look more like research institutes than companies, and they live or die on whether the science produces results before the patience (or the founder) runs out.

And there is a telling fourth development: the move to outside money. In 2026, Blue Origin was reported to be seeking outside investment for the first time in its 26-year history, a sign that even a fortune the size of Bezos’s has limits when the burn rate climbs high enough. When a pure self-funded moonshot starts taking outside capital, it has crossed from personal project into actual industry.

What it costs

The numbers are the most honest part of the subject, and they span an enormous range depending on the lane.

Space is the most expensive. Blue Origin reportedly burns around $4.8 billion a year, with cumulative investment approaching $28 billion — and only launched its orbital New Glenn rocket in 2025, years behind schedule. SpaceX operates at a similar scale but offsets it with revenue; its reported 2025 figures — roughly $16 billion in revenue against heavy reinvestment — show what a moonshot looks like once it has a working business attached. These are national-space-agency budgets, run privately.

Longevity runs in the low billions per lab. Altos Labs launched with a $3 billion funding round in January 2022, one of the largest startup launches in biotech history. Calico was set up with about $1.5 billion in committed funding from Google and the drugmaker AbbVie. Saudi Arabia’s Hevolution has signaled spending on the order of $1 billion a year. At the personal end, Bryan Johnson’s roughly $2 million a year on his own protocol is a rounding error by comparison — and a reminder of how much cheaper it is to optimize one body than to cure aging.

Fusion sits in between. Helion has raised more than $1 billion, including $375 million from Altman personally — his largest startup bet — and a further $425 million round in early 2025. Its rival Commonwealth Fusion Systems, a spinout from MIT, has raised more than $2 billion overall, including a 2025 round of roughly $863 million with Google among the backers. Using the bracket shorthand this site favors: a serious longevity lab or fusion startup is a $1B–$3B undertaking, while a frontier space program is a $5B-a-year-and-up commitment sustained across a decade.

Hidden costs and tradeoffs

The capital is only the visible cost. The harder ones are structural.

The first is opportunity cost made very public. Spending billions to reach Mars or defeat aging invites an obvious question — why not spend it on problems we already know how to solve? The “trying to live forever while people lack clean water” critique is the single most common attack on the whole category, and it lands harder on the longevity lane than on, say, fusion, which has an obvious public benefit if it works. Founders in this space spend real reputational energy defending the choice.

The second is the overpromising trap. Moonshots run on bold timelines — fusion power “within a decade,” aging “solved” in a generation, a city on Mars by a date that keeps moving. When those dates slip, as they almost always do, the gap between the promise and the result becomes its own liability. A fusion startup that pledged power by a certain year and missed it has spent down credibility it can’t easily rebuild.

The third is reputational entanglement. When the founder is the project, the project’s stumbles become the founder’s, and vice versa. A high-profile failure, a safety incident, or simply years of visible burn with little to show can attach to the person far more than a quiet failed investment would.

And the fourth, specific to the self-funded model, is the limit even great wealth runs into. Blue Origin’s move toward outside investment is the tell: a $4.8 billion annual burn is a lot even against a fortune in the hundreds of billions, and at some point the moonshot has to either become a real business or stop being a personal project. Patience is the rarest resource in the category, and it is not infinite.

There is also a subtler tradeoff: concentration of direction. When one person funds a national-scale effort alone, they also decide alone what it aims at, which experiments get run, and which get killed. A government program answers, however imperfectly, to the public; a privately funded moonshot answers to its founder’s convictions. That can be a feature — it’s why these projects move fast — but it means the agenda for whole frontiers of science can rest on the enthusiasms of a handful of people, with no vote and no appeal.

What people get wrong

The biggest misconception is that moonshot just means vanity project. Some are; many aren’t. The clearest counterexample is SpaceX, which did not merely promise reusable rockets — it built them, flew them, landed them, and now launches the majority of the world’s payload to orbit while running a satellite internet business with real customers. Whatever one thinks of its founder, the infrastructure is real and shipping. The test that separates the two is simple and unsentimental: does anything actually launch, cure, or generate power, or is it still a countdown clock and a keynote?

The second misconception is the mirror image — that because the science is real, the promises are reliable. Longevity research is genuine, well-funded, and staffed by serious scientists; cellular reprogramming and the biology of aging are legitimate frontiers. But “real science” and “you will live to 150” are very different claims, and the marketing around personal longevity often races far ahead of what any lab has demonstrated. Treat the research as promising and the immortality talk as advertising.

The third is that this is only a Silicon Valley story. It isn’t. Gulf sovereign wealth funds are now among the largest backers of longevity science; fusion startups have spun out of MIT and university labs across several countries; and the space race has serious private and state players well beyond the U.S. The American tech-billionaire version is the loudest, but the money and the ambition are global — a pattern that echoes how extreme fortunes themselves are increasingly distributed worldwide.

The fourth is the most basic: “moonshot” is also a marketing word. The label confers seriousness, and plenty of projects adopt it precisely because it makes a bet sound visionary rather than reckless. The word does not certify the work. A press release calling something a moonshot tells you how it wants to be seen, not whether it will ever ship.

Bottom line

The Million Dollar Question’s answer is D: Blue Origin reportedly burns through about $4.8 billion a year, and after 26 years and roughly $28 billion in cumulative investment, it is profitable in no year and was, as of 2026, seeking outside money for the first time. That single number captures the whole category: a sum larger than many national space budgets, spent year after year, on a goal that may or may not arrive.

When a fortune becomes large enough, the interesting question stops being what it can buy and becomes what it can attempt. Megaprojects are the answer some of the largest fortunes give — and they are simultaneously the most generous and the most self-aggrandizing thing wealth does, often in the same breath. The way to read them is to ignore the rhetoric and watch the hardware. The real moonshots